Array BioPharma (NASDAQ:ARRY) Earning Positive News Coverage, Study Finds
Media stories about Array BioPharma (NASDAQ:ARRY) have been trending positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Array BioPharma earned a news sentiment score of 0.26 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 47.9469242352872 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Should You Buy Achillion Pharmaceuticals, Inc. (ACHN) or Array BioPharma Inc. (ARRY)? – StockNewsGazette (stocknewsgazette.com)
- Array BioPharma Inc (ARRY) Files 10-K for the Fiscal Year Ended on June 30, 2017 – Nasdaq (nasdaq.com)
- Array BioPharma Inc. (ARRY) Upgraded at Zacks Investment Research (americanbankingnews.com)
- Array BioPharma Inc. to Post FY2021 Earnings of $0.73 Per Share, Jefferies Group Forecasts (NASDAQ:ARRY) (americanbankingnews.com)
- Array BioPharma Inc. (NASDAQ:ARRY) to Post FY2018 Earnings of ($1.25) Per Share, SunTrust Banks Forecasts (americanbankingnews.com)
ARRY has been the topic of several recent analyst reports. J P Morgan Chase & Co upgraded Array BioPharma from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $9.00 to $10.00 in a report on Wednesday, May 3rd. Zacks Investment Research downgraded Array BioPharma from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. BidaskClub upgraded Array BioPharma from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. ValuEngine upgraded Array BioPharma from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Piper Jaffray Companies set a $14.00 price objective on Array BioPharma and gave the stock a “buy” rating in a report on Wednesday, May 31st. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $11.54.
Array BioPharma (NASDAQ:ARRY) traded up 3.36% during trading on Friday, reaching $8.62. The company’s stock had a trading volume of 3,390,528 shares. Array BioPharma has a 52 week low of $3.10 and a 52 week high of $13.40. The firm’s market cap is $1.47 billion. The stock’s 50 day moving average is $8.24 and its 200-day moving average is $9.07.
Array BioPharma (NASDAQ:ARRY) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.04. The company had revenue of $33.80 million for the quarter, compared to analyst estimates of $28.64 million. Array BioPharma had a negative return on equity of 1,267.92% and a negative net margin of 77.44%. Array BioPharma’s revenue was down 21.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.17) earnings per share. On average, equities research analysts forecast that Array BioPharma will post ($1.00) earnings per share for the current fiscal year.
Array BioPharma Company Profile
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).
Receive News & Ratings for Array BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.